Supplemental Figure 2 from Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
Year: 2023
Type: supplementary-materials
Abstract: Serial BRAF V600E levels (pg) compared to tumor volume by RECIST from 11 patients treated with vemurafenib and 6 patients treated with dabrafenib and trametinib until removed from the study due to progressive disease (the time of disease progression is shown with an arrow).
Authors: David J. Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, Aislyn P. Schalck, Laleh Montaser-Kouhsari, Alireza Sepehr, Donald P. Lawrence, David F. McDermott, Rachel Cohen, Alexander Carlson, Jennifer A. Wargo, Ryan Merritt, Virginia J. Seery, F. Stephen Hodi, Anasuya Gunturi, Dennie Fredrick, Michael B. Atkins, A. John Iafrate, Keith T. Flaherty, James W. Mier, Ryan J. Sullivan
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362481560